Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial - Cohen, SB; Dore, RK; Lane, NE (Arthritis Rheum, 2008)
et al.